SCHEMBL286520

SCHEMBL286520

COc1ccc(C2=CC(=O)C(C)(C)O2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.55
KDM4E B2RXH2 2/20 0.55
ALDH1A1 P00352 4/20 0.54
HTT P42858 2/20 0.54
TDP1 Q9NUW8 5/20 0.52
BACE1 P56817 2/20 0.46
DRD2 P14416 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
GLA P06280 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MAPT P10636 4/20 0.42
MEN1 O00255 1/20 0.42
PKM P14618 1/20 0.42
MAPK1 P28482 1/20 0.42
KMT2A Q03164 1/20 0.42
MCL1 Q07820 1/20 0.42
EGFR P00533 1/20 0.42
POLB P06746 1/20 0.42
HSP90AA1 P07900 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19337441 0.79 HPGD (0.48) HPGDKDM4EALDH1A1HTTTDP1
SCHEMBL7897120 0.79 SIGMAR1 (0.36) HPGDKDM4EALDH1A1HTTTDP1
SCHEMBL1419922 0.76 GSTP1 (0.51) HPGDDRD2SIGMAR1LMNAPTPN1
SCHEMBL286625 0.75 SIGMAR1 (0.36) HPGDKDM4EALDH1A1TDP1DRD2
SCHEMBL27602764 0.75 BACE1 (0.40) BACE1LMNANOTUM
SCHEMBL7001594 0.75 SIGMAR1 (0.34) HPGDKDM4EALDH1A1HTTTDP1
SCHEMBL27466573 0.73 SIGMAR1 (0.36) HPGDKDM4EALDH1A1HTTDRD2
SCHEMBL27467008 0.73 SIGMAR1 (0.36) HPGDKDM4EALDH1A1HTTDRD2
SCHEMBL5321421 0.72 KDM4E (0.51) HPGDKDM4EALDH1A1HTTTDP1
SCHEMBL1419931 0.72 ALDH1A1 (0.43) KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2164817-A None JP disclosed
EP-2297133-B1 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS FORUM PHARMACEUTICALS INC (US) 2017-09-13 EP disclosed
EP-2297133-B1 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS FORUM PHARMACEUTICALS INC (US) 2017-09-13 EP disclosed
EP-3020716-A1 PHENOXYMETHYL HETEROCYCLIC COMPOUNDS Forum Pharmaceuticals Inc. (US) 2016-05-18 EP disclosed
EP-3020716-A1 PHENOXYMETHYL HETEROCYCLIC COMPOUNDS Forum Pharmaceuticals Inc. (US) 2016-05-18 EP disclosed
US-9265767-B2 1,2-disubstituted heterocyclic compounds FORUM PHARMACEUTICALS INC. (US) 2016-02-23 US disclosed
US-9265767-B2 1,2-disubstituted heterocyclic compounds FORUM PHARMACEUTICALS INC. (US) 2016-02-23 US disclosed
CN-105125547-A FORUM PHARMACEUTICALS INC FORUM PHARMACEUTICALS INC 2015-12-09 CN disclosed
US-20150322069-A1 PHENOXYMETHYL HETEROCYCLIC COMPOUNDS FMR LLC 2015-11-12 US disclosed
US-20150322069-A1 PHENOXYMETHYL HETEROCYCLIC COMPOUNDS FMR LLC 2015-11-12 US disclosed
US-20100292238-A1 Phenoxymethyl Heterocyclic Compounds FMR LLC 2010-11-18 US disclosed
US-20100292238-A1 Phenoxymethyl Heterocyclic Compounds FMR LLC 2010-11-18 US disclosed
WO-2010128995-A1 PHENOXYMETHYL HETEROCYCLIC COMPOUNDS ENVIVO PHARMACEUTICALS, INC. (US) 2010-11-11 WO disclosed
WO-2010128995-A1 PHENOXYMETHYL HETEROCYCLIC COMPOUNDS ENVIVO PHARMACEUTICALS, INC. (US) 2010-11-11 WO disclosed
US-20100137317-A1 1,2-Disubstituted Heterocyclic Compounds ENVIVO PHARMACEUTICALS, INC. (US) 2010-06-03 US disclosed
US-20100137317-A1 1,2-Disubstituted Heterocyclic Compounds ENVIVO PHARMACEUTICALS, INC. (US) 2010-06-03 US disclosed
US-20100137317-A1 1,2-Disubstituted Heterocyclic Compounds ENVIVO PHARMACEUTICALS, INC. (US) 2010-06-03 US disclosed
WO-2009158393-A1 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS ENVIVO PHARMACEUTICALS, INC. (US) 2009-12-30 WO disclosed
WO-2009158393-A1 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS ENVIVO PHARMACEUTICALS, INC. (US) 2009-12-30 WO disclosed
JP-H02164817-A ULTRAVIOLET RAY ABSORBER T HASEGAWA CO LTD 1990-06-25 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322069-A1 PHENOXYMETHYL HETEROCYCLIC COMPOUNDS PDE3A, PDE2A, PDE5A HPGD 74/4885KDM4E 559/4885ALDH1A1 821/4885
US-20100292238-A1 Phenoxymethyl Heterocyclic Compounds PDE3A, PDE2A, PDE5A HPGD 74/4885KDM4E 559/4885ALDH1A1 821/4885
US-20100137317-A1 1,2-Disubstituted Heterocyclic Compounds PDE12, PDE7A, PDE10A HPGD 142/4885KDM4E 1865/4885ALDH1A1 699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.